Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,418 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluid administration Clear all

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania

Conditions: Cirrhosis, Liver, Acute Kidney Injury, Hepatorenal Syndrome
Interventions: Recommendation: No Further Resuscitation, Recommendation: Resuscitation with Crystalloid, Recommendation: Resuscitation with Colloid, Recommendation: Standard of Care IV Albumin; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Shock, Fluid Overload, Cardiac Output, Low
Interventions: Trendelenburg positioning VTI; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Glioblastoma, IDH-Wildtype
Interventions: Archive Sample Retrieval, Biospecimen Collection, Chest Radiography, Echocardiography Test, EGFR/EGFRvIII Inhibitor WSD0922-FU, Magnetic Resonance Imaging, Temozolomide; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: HeartFlow, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Redwood City, California • Stanford, California • Durham, North Carolina

Conditions: Sepsis
Interventions: ECHO, Blood Draw; Procedure
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 7
States / cities: Boston, Massachusetts • The Bronx, New York • Winston-Salem, North Carolina + 4 more

Conditions: Anesthesia
Interventions: Normal Saline, Lactated Ringer, Normosol-R Inj; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 10 Years to 21 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: HIV Infection
Interventions: Efavirenz; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 3 Years to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 27
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: NIS793, Nab-paclitaxel, Gemcitabine, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Los Angeles, California • Orlando, Florida + 6 more

Conditions: Relapsed Neuroblastoma, Metastatic Pheochromocytoma
Interventions: 131 I-Metaiodobenzylguanidine (131I-MIBG), Potassium iodide solution, G-CSF, hematopoietic stem cell infusion; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 1 Year and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: End Stage Kidney Disease (ESKD), Hypertension (HTN), Peritoneal Dialysis (PD)
Interventions: Target systolic blood pressure <120 mmHg., Target systolic blood pressure <140 mmHg; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: San Francisco, California

Conditions: Unexplained Infertility, Polycystic Ovarian Syndrome, Anovulatory
Interventions: Placebo, Nimodipine; Drug
Lead sponsor: Boston IVF; Other
Eligibility: 25 Years to 40 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Post-stroke Depression
Interventions: Ketamine; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Acute Myocardial Infarction
Interventions: Selatogrel, Placebo; Combination Product
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 25,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 82
States / cities: Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 73 more

Conditions: Encopresis, ASD
Interventions: Glycerin Suppository, Behavioral strategies; Drug · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Postoperative Ileus
Interventions: Regular Coffee, Decaffeinated coffee, Warm water; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Tobacco Dependence Caused by Cigarettes
Interventions: NJOY ACE commercial e-cigarette; Device
Lead sponsor: University of Nevada, Reno; Other
Eligibility: 21 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Acute Kidney Injury
Interventions: 0.9% Normal Saline (0.9% Sodium Chloride) injection, Isolyte S injection; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Burns
Interventions: NICOM (non-invasive cardiac output monitor); Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Clostridiodies Difficile Infections
Interventions: MTC 01, Fecal Microbiota Transplantation (FMT); Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Surgery, Quality Improvement, Perioperative Care, ERAS
Interventions: ERAS perioperative care, Standard perioperative care, Noninvasive hemodynamic monitoring; Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Insulin Resistance, Obesity
Interventions: Roux-en-Y Gastric Bypass (RYGBP), Sleeve Gastrectomy (SG), Very Low Calorie Diet (VLCD); Procedure · Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Aging
Interventions: Sham, Therapeutic Plasma Exchange, IVIG; Device · Drug
Lead sponsor: Dobri Kiprov; Industry
Eligibility: 50 Years to 95 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Mill Valley, California

Conditions: Healthy Volunteers, Breast Cancer, Metastatic
Interventions: Blood draw; Diagnostic Test
Lead sponsor: Angle plc; Industry
Eligibility: 22 Years and older · Female only
Enrollment: 421 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois • Rochester, New York + 1 more

Search by objective public record fields.

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

Initial Resuscitation for Acute Kidney Injury in Cirrhosis

Evaluating Fluid Responsiveness in ICU Patients Using VTI and Trendelenburg Positioning

Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

The PLATFORM Study: Prospective LongitudinAl Trial of FFRct: Outcome and Resource IMpacts)

Study of Treatment's Echocardiographic Mechanisms

Impact of Intraoperative Fluid Management on Electrolyte and Acid-base Variables

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

MIBG for Refractory Neuroblastoma and Pheochromocytoma

Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial

Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT

Use of Transmucosal Ketamine in Post Stroke Depression

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

Comprehensive Toileting Program

The Effect of Coffee Consumption in Enhancing Recovery of Bowel Function Following Colorectal Surgery.

Feasibility and Acceptability of Switching to E-cigarettes Among Cigarette Smokers Engaged in SUD Treatment

Fluid Chloride and AKI in Cardiopulmonary Bypass

Cardiac Output Monitoring in Burn Patients

MTC Versus FMT in for RCDI

Enhanced Recovery After Surgery in Colorectal Surgery: A Large-Scale Quality Improvement Project

Metabolism and Bariatric Surgery Study

The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics

Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System